Hella Kohlhof

958 total citations
40 papers, 686 citations indexed

About

Hella Kohlhof is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Hella Kohlhof has authored 40 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Hella Kohlhof's work include Histone Deacetylase Inhibitors Research (8 papers), Epigenetics and DNA Methylation (7 papers) and Biochemical and Molecular Research (6 papers). Hella Kohlhof is often cited by papers focused on Histone Deacetylase Inhibitors Research (8 papers), Epigenetics and DNA Methylation (7 papers) and Biochemical and Molecular Research (6 papers). Hella Kohlhof collaborates with scholars based in Germany, United States and Australia. Hella Kohlhof's co-authors include Daniel Vitt, Nikolaus Rieber, Ursula Just, Timm Schroeder, Evelyn Peelen, Michèle J. Hoffmann, Maria Pinkerneil, Wolfgang A. Schulz, Günter Niegisch and René Bartz and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Hella Kohlhof

38 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hella Kohlhof Germany 16 482 136 89 88 64 40 686
A. Shamseddine United States 14 365 0.8× 110 0.8× 76 0.9× 118 1.3× 76 1.2× 39 686
Ankur Sharma United States 14 365 0.8× 227 1.7× 83 0.9× 84 1.0× 70 1.1× 37 686
Ling Yin China 12 232 0.5× 92 0.7× 107 1.2× 69 0.8× 48 0.8× 24 511
Sharon Wu United States 13 274 0.6× 247 1.8× 56 0.6× 58 0.7× 42 0.7× 68 604
Osman Çen United States 14 233 0.5× 217 1.6× 183 2.1× 91 1.0× 102 1.6× 25 637
Rita Bisogni Italy 14 502 1.0× 192 1.4× 239 2.7× 69 0.8× 62 1.0× 25 868
Tessa Knox United States 9 606 1.3× 256 1.9× 118 1.3× 61 0.7× 24 0.4× 18 861
Hirokazu Hirata Japan 10 589 1.2× 143 1.1× 275 3.1× 75 0.9× 43 0.7× 14 834
Liza D. Morales United States 12 406 0.8× 149 1.1× 190 2.1× 81 0.9× 50 0.8× 20 736
Alan K. Ikeda United States 11 396 0.8× 120 0.9× 41 0.5× 84 1.0× 31 0.5× 20 614

Countries citing papers authored by Hella Kohlhof

Since Specialization
Citations

This map shows the geographic impact of Hella Kohlhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hella Kohlhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hella Kohlhof more than expected).

Fields of papers citing papers by Hella Kohlhof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hella Kohlhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hella Kohlhof. The network helps show where Hella Kohlhof may publish in the future.

Co-authorship network of co-authors of Hella Kohlhof

This figure shows the co-authorship network connecting the top 25 collaborators of Hella Kohlhof. A scholar is included among the top collaborators of Hella Kohlhof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hella Kohlhof. Hella Kohlhof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schreieck, Amelie, Evelyn Peelen, João Quinta da Fonseca, et al.. (2025). DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study. Journal of Crohn s and Colitis. 19(Supplement_1). i106–i106.
2.
Stiller, Tracey, Christian Gege, Wael Saeb, et al.. (2025). Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity. Journal of Medicinal Chemistry. 68(15). 16212–16226. 1 indexed citations
3.
Herrmann, Alexandra, et al.. (2024). Molecular analysis of the 2022 mpox outbreak and antiviral activity of dihydroorotate dehydrogenase inhibitors against orthopoxviruses. Antiviral Research. 233. 106043–106043. 5 indexed citations
4.
5.
Polasek, Thomas M., et al.. (2023). EP63 FIRST IN HUMAN TRIAL OF IMU-856, AN ORALLY AVAILABLE REGULATOR OF BARRIER FUNCTION FOR THE TREATMENT OF CELIAC DISEASE. Gastroenterology. 164(6). S–1204. 2 indexed citations
6.
7.
Vehreschild, Maria J. G. T., P.A. Atanasov, Cristian Oancea, et al.. (2022). Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infectious Diseases and Therapy. 11(6). 2159–2176. 8 indexed citations
8.
Polasek, Thomas M., et al.. (2021). 057 First clinical experience with IMU-935, an orally available small molecule inhibitor of IL-17. Journal of Investigative Dermatology. 141(10). S158–S158. 1 indexed citations
9.
Kim, Yu-Jin, Beatrice Cubitt, Yíngyún Caì, et al.. (2020). Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro. Viruses. 12(8). 821–821. 6 indexed citations
10.
Kohlhof, Hella, et al.. (2020). Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 45(5). 557–573. 22 indexed citations
11.
Peelen, Evelyn, et al.. (2020). Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 43. 102129–102129. 46 indexed citations
12.
Hahn, Friedrich, Christina Wangen, Antonia Sophia Peter, et al.. (2020). IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses. 12(12). 1394–1394. 41 indexed citations
13.
14.
Gruber, Wolfgang, Christina Sternberg, Sonia Coni, et al.. (2017). Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance. International Journal of Cancer. 142(5). 968–975. 39 indexed citations
15.
Mishra, Vivek Kumar, Florian Wegwitz, Robyn Laura Kosinsky, et al.. (2017). Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Research. 45(11). 6334–6349. 65 indexed citations
16.
Pinkerneil, Maria, Michèle J. Hoffmann, Hella Kohlhof, Wolfgang A. Schulz, & Günter Niegisch. (2016). Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Targeted Oncology. 11(6). 783–798. 51 indexed citations
17.
Kohlhof, Hella, et al.. (2016). 4SC-202: Epigenetic modulation to pave the way for checkpoint inhibition.. Journal of Clinical Oncology. 34(15_suppl). 11546–11546. 1 indexed citations
18.
Tresckow, Bastian von, Dennis A. Eichenauer, Walter E. Aulitzky, et al.. (2014). First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).. Journal of Clinical Oncology. 32(15_suppl). 8559–8559. 8 indexed citations
19.
Kohlhof, Hella, et al.. (2013). A Novel Microtubule Inhibitor 4SC-207 with Anti-Proliferative Activity in Taxane-Resistant Cells. PLoS ONE. 8(11). e79594–e79594. 5 indexed citations
20.
Schroeder, Timm, Hella Kohlhof, Nikolaus Rieber, & Ursula Just. (2003). Notch Signaling Induces Multilineage Myeloid Differentiation and Up-Regulates PU.1 Expression. The Journal of Immunology. 170(11). 5538–5548. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Shamseddine Breakdown of academic impact, for papers by Ankur Sharma Breakdown of academic impact, for papers by Ling Yin Breakdown of academic impact, for papers by Sharon Wu Breakdown of academic impact, for papers by Osman Çen Breakdown of academic impact, for papers by Rita Bisogni Breakdown of academic impact, for papers by Tessa Knox Breakdown of academic impact, for papers by Hirokazu Hirata Breakdown of academic impact, for papers by Liza D. Morales Breakdown of academic impact, for papers by Alan K. Ikeda
Rankless by CCL
2026